TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26470874

Group type: EXPERIMENTAL
Intervention: Single ascending doses of 20(S)-ginsenoside Rg3 (10-60 mg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Multiple doses of 20(S)-ginsenoside Rg3 (30 mg for 15 days)
Number of subjects: 33
Study: 25093627

Group type: EXPERIMENTAL
Intervention: Imagery group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 22747890

Group type: EXPERIMENTAL
Intervention: Carbohydrate drink
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tap water
Number of subjects: 60

Group type: COMPARATOR
Intervention: Preoperative fasting
Number of subjects: 60
Study: 19622526

Group type: EXPERIMENTAL
Intervention: Neuromuscular warm-up programme (1-3 times per week for 6 months, 25 min per session)
Number of subjects: 222
Study: 17612905

Group type: EXPERIMENTAL
Intervention: Single-tablet combination therapy
Number of subjects: 10704
Study: 15364437

Group type: EXPERIMENTAL
Intervention: 3-week vaccination schedule (0, 1, 3 weeks) with 20microg Engerix B i.m.
Number of subjects: 585

Group type: COMPARATOR
Intervention: 6-month vaccination schedule (0, 1, 6 months) with 20microg Engerix B i.m.
Number of subjects: 585
Study: 11739118

Group type: EXPERIMENTAL
Intervention: Amino acid infusion
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Glucagon infusion
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (normal subjects)
Number of subjects: 24
Study: 10408547

Group type: EXPERIMENTAL
Intervention: Danaparoid
Number of subjects: 227

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study: 7487853

Group type: EXPERIMENTAL
Intervention: High Responsibility (HR) group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low Responsibility (LR) group
Number of subjects: 0
Study: 2248077

Group type: EXPERIMENTAL
Intervention: Moclobemide 300‐500 mg daily for 4 weeks
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Moclobemide 150‐300 mg daily for 6 weeks
Number of subjects: 119

Group type: COMPARATOR
Intervention: Mianserin 75‐125 mg daily for 4 weeks
Number of subjects: 119

Group type: COMPARATOR
Intervention: Maprotiline 75‐150 mg daily for 6 weeks
Number of subjects: 119
Study: 7248705

Group type: EXPERIMENTAL
Intervention: Cooled irrigating fluid at 8 degrees C
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ambient temperature irrigating fluid
Number of subjects: 40
Study: 29659888

Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg daily
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 26490018

Group type: COMPARATOR
Intervention: Probiotic drink containing Lactobacillus casei Shirota, administered twice a day for 4 weeks.
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo drink, administered for 4 weeks.
Number of subjects: 71
Study: 24626000

Group type: EXPERIMENTAL
Intervention: Theophyline (4 mg/kg IV loading dose, followed by 200 mg orally three times daily for four days)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 20550483

Group type: EXPERIMENTAL
Intervention: Orodispersible tablets (ODTs) incorporating PEG solid dispersion of meloxicam (MLX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Marketed immediate release MLX tablet
Number of subjects: 0
Study: 20386003

Group type: EXPERIMENTAL
Intervention: Enhanced depression treatment (problem-solving therapy and/or pharmacotherapy, then a stepped-care approach)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Enhanced depression treatment
Number of subjects: 237

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 237
Study: 18451780

Group type: EXPERIMENTAL
Intervention: Orlistat (Xenical) for 6 months
Number of subjects: 95

Group type: COMPARATOR
Intervention: No specific medication (Control)
Number of subjects: 95
Study: 16170170

Group type: EXPERIMENTAL
Intervention: Highest quartile of plasma total carotenoid concentration
Number of subjects: 1551
Study: 12952293

Group type: EXPERIMENTAL
Intervention: IL-4 Pseudomonas exotoxin (NBI-3001) administered intratumorally via convection-enhanced delivery at doses of 6 microg/ml x 40 ml, 9 microg/ml x 40 ml, 15 microg/ml x 40 ml, or 9 microg/ml x 100 ml.
Number of subjects: 31
Study: 11028576

Group type: EXPERIMENTAL
Intervention: Intracutaneous injection
Number of subjects: 100

Group type: COMPARATOR
Intervention: Subcutaneous injection
Number of subjects: 100
Study: 8630719

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg qd
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg bid
Number of subjects: 311

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Overall treatment effect
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 311
Study: 1428726

Group type: EXPERIMENTAL
Intervention: Difluorodeoxycytidine (dFdC) administered by 30 minute infusion at doses of 5-90 mg/m2
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Difluorodeoxycytidine (dFdC) administered by 5 minute bolus at doses of 30-150 mg/m2
Number of subjects: 50
Study: 6385309

Group type: EXPERIMENTAL
Intervention: Oxprenolol plus ethanol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lorazepam plus ethanol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3089049

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both agents
Number of subjects: 50
Study: 29152718

Group type: EXPERIMENTAL
Intervention: KLOX BioPhotonic System (LED blue light phototherapy with photo-converter chromophores), treated hemiface, 12 weeks total (6 weeks treatment + 6 weeks follow-up)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control hemiface (untreated during Main trial), received 6 weeks of treatment (twice weekly)
Number of subjects: 49
Study: 26692004

Group type: EXPERIMENTAL
Intervention: Henagliflozin 5 mg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Henagliflozin 10 mg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Henagliflozin 20 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 25182100

Group type: EXPERIMENTAL
Intervention: Active vagal nerve block device
Number of subjects: 239

Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 239
Study: 22732370

Group type: EXPERIMENTAL
Intervention: Abdominal binder
Number of subjects: 14
Study: 20211542

Group type: EXPERIMENTAL
Intervention: Arthrocentesis plus intra‐articular injection of tenoxicam
Number of subjects: 21

Group type: COMPARATOR
Intervention: Arthrocentesis alone
Number of subjects: 21
Study: 19183313

Group type: EXPERIMENTAL
Intervention: Bemiparin 3500 IU/day for 10 days, followed by 2500 IU/day for up to 3 months plus standard care for ulcers
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo plus standard care for ulcers
Number of subjects: 70
Study: 15914614

Group type: EXPERIMENTAL
Intervention: Oral angiotensin II receptor blocker (ARB)
Number of subjects: 698

Group type: COMPARATOR
Intervention: AGTR2/3123A genotype
Number of subjects: 698

Group type: COMPARATOR
Intervention: AGTR2/3123C‐‐>A polymorphism
Number of subjects: 698

Group type: COMPARATOR
Intervention: ACE/ID+DD (D carriers)
Number of subjects: 698
Study: 12578433

Group type: EXPERIMENTAL
Intervention: Sodium lactate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cholecystokinin tetrapeptide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10902989

Group type: EXPERIMENTAL
Intervention: Energy and micronutrient supplement (1171 kJ + 12 mg iron)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Energy and micronutrient supplement (209 kJ + 12 mg iron)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Energy and micronutrient supplement (104 kJ)
Number of subjects: 136
Study: 8770304

Group type: EXPERIMENTAL
Intervention: 30 mg of ketorolac administered via Jackson‐Pratt drain or intravenously
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (normal saline) administered via Jackson‐Pratt drain or intravenously
Number of subjects: 60
Study: 1315652

Group type: EXPERIMENTAL
Intervention: Arginine supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard diet (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (Arginine and Control)
Number of subjects: 0
Study: 3907354

Group type: COMPARATOR
Intervention: Rocket clip
Number of subjects: 663

Group type: COMPARATOR
Intervention: Tubal ring
Number of subjects: 663
Study: 30485400

Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg at weeks 0 and 4 and every 8 weeks thereafter
Number of subjects: 0

Group type: COMPARATOR
Intervention: adalimumab 80 mg at week 0, 40 mg at week 1, and 40 mg every 2 weeks thereafter
Number of subjects: 0
Study: 29861315

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring insertion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heel stick
Number of subjects: 0
Study: 26861939

Group type: EXPERIMENTAL
Intervention: Morning dosing of antihypertensive medication
Number of subjects: 10269

Group type: COMPARATOR
Intervention: Evening dosing of antihypertensive medication
Number of subjects: 10269
Study: 23294350

Group type: EXPERIMENTAL
Intervention: Topical sialogogue spray containing 1% malic acid
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 41
Study: 22270505

Group type: EXPERIMENTAL
Intervention: GlideScope Cobalt® video laryngoscope (GCV)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Direct laryngoscopy with a Miller blade (DL)
Number of subjects: 60
Study: 20462041

Group type: COMPARATOR
Intervention: Epidural infusion of midazolam (0.04 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuous electroacupuncture (EA) at 30‐100 Hz on Zusanli (ST36) and Sanyinjiao (SP6) acupoints
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined epidural infusion and EA
Number of subjects: 60
Study: 18781432

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16269640

Group type: EXPERIMENTAL
Intervention: Neuroprotection trials
Number of subjects: 42
Study: 12419082

Group type: EXPERIMENTAL
Intervention: sequential estradiol‐norethisterone acetate regimen
Number of subjects: 42

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42
Study: 10993623

Group type: EXPERIMENTAL
Intervention: Minimum 5-day IV antibiotic course (Group 1)
Number of subjects: 94

Group type: COMPARATOR
Intervention: No minimum IV antibiotic requirement (Group 2)
Number of subjects: 94
Study: 9011436

Group type: EXPERIMENTAL
Intervention: Calcisorb
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1459376

Group type: EXPERIMENTAL
Intervention: Methyl isobutyl ketone (MIBK) at 100 ppm
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Methyl ethyl ketone (MEK) at 200 ppm
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: MIBK at 50 ppm with MEK at 100 ppm
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo (5‐min presentation of 25 ppm MEK‐MIBK)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Ethanol by ingestion (95%‐0.84 ml/kg)
Number of subjects: 143
Study: 3976470

Group type: EXPERIMENTAL
Intervention: Exercise intervention group (n = 19)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group (n = 22)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 156
Study: 31515006

Group type: EXPERIMENTAL
Intervention: Informative intervention through Short Message Service (SMS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no SMS intervention)
Number of subjects: 0
Study: 30010751

Group type: EXPERIMENTAL
Intervention: Nintedanib (200 mg twice daily)
Number of subjects: 768

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 768
Study: 28119496

Group type: EXPERIMENTAL
Intervention: Combination therapy with 125 mg of bosentan twice daily plus 10 μg of iloprost 4‐6 times/d
Number of subjects: 27

Group type: COMPARATOR
Intervention: Bosentan monotherapy with 125 mg of bosentan twice daily
Number of subjects: 27

Group type: COMPARATOR
Intervention: Iloprost monotherapy with 10 μg of iloprost 4‐6 times/d
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 27
Study: 25676452

Group type: EXPERIMENTAL
Intervention: Interference condition (learning and retrieving an alternative mock crime)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Time-delay conditions
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Memory-interference manipulation
Number of subjects: 120
Study: 23283501

Group type: EXPERIMENTAL
Intervention: Oral-lipid-tolerance tests (OLTTs)
Number of subjects: 51
Study: 21914118

Group type: EXPERIMENTAL
Intervention: Interlaminar (IL) epidural steroid injection
Number of subjects: 64

Group type: COMPARATOR
Intervention: Transforaminal (TF) epidural steroid injection
Number of subjects: 64
Study: 18640304

Group type: EXPERIMENTAL
Intervention: Digital air leak system
Number of subjects: 100

Group type: COMPARATOR
Intervention: Analogue air leak system
Number of subjects: 100
Study: 16511340

Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60
Study: 12971730

Group type: EXPERIMENTAL
Intervention: Nocturnal BCAA administration
Number of subjects: 12

Group type: COMPARATOR
Intervention: Daytime BCAA administration
Number of subjects: 12
Study: 10755543

Group type: EXPERIMENTAL
Intervention: MMF 1 g/day
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: MMF 2 g/day
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: AZA
Number of subjects: 176

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 176
Study: 9294478

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (40 mg days -1, 0, 1, 7, 8, and 9 of each cycle)
Number of subjects: 83

Group type: COMPARATOR
Intervention: No methylprednisolone
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Both arms (A and B)
Number of subjects: 83
Study: 8360006

Group type: EXPERIMENTAL
Intervention: Tetracycline fiber only
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Scaling and root planing and tetracycline fibers
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Root planing only
Number of subjects: 8

Group type: COMPARATOR
Intervention: Nontreatment (controls)
Number of subjects: 8
Study: 3491907

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional analgesia
Number of subjects: 0
Study: 30509634

Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI) at 10°C
Number of subjects: 8

Group type: COMPARATOR
Intervention: Thermoneutral Water Immersion (TWI) at 28°C
Number of subjects: 8
Study: 28194688

Group type: EXPERIMENTAL
Intervention: ED-initiated buprenorphine with 10-week continuation in primary care
Number of subjects: 290

Group type: COMPARATOR
Intervention: Referral
Number of subjects: 290

Group type: COMPARATOR
Intervention: Brief intervention
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: ED-initiated buprenorphine
Number of subjects: 290
Study: 25425434

Group type: EXPERIMENTAL
Intervention: Azithromycin (AZ) 1,000 mg plus chloroquine (CQ) 600 mg base once daily for three days
Number of subjects: 467

Group type: COMPARATOR
Intervention: Mefloquine hydrochloride (MQ) 1,250 mg (split dose)
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Azithromycin (AZ) 500 mg plus chloroquine (CQ) 600 mg base once daily for three days
Number of subjects: 467

Group type: COMPARATOR
Intervention: Mefloquine hydrochloride (MQ)
Number of subjects: 467
Study: 24349598

Group type: EXPERIMENTAL
Intervention: High-dose prednisolone (2 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20107293

Group type: EXPERIMENTAL
Intervention: Combination therapies for PHN pain relief
Number of subjects: 0
Study: 18390971

Group type: EXPERIMENTAL
Intervention: Cetuximab (400 mg/m² day 1 followed by 250 mg/m² weekly) plus Irinotecan (350 mg/m² every 3 weeks)
Number of subjects: 1298

Group type: COMPARATOR
Intervention: Irinotecan alone
Number of subjects: 1298

Group type: EXPERIMENTAL
Intervention: Cetuximab plus Irinotecan
Number of subjects: 1298
Study: 16797948

Group type: EXPERIMENTAL
Intervention: Sustained-release metformin hydrochloride pellets (F-2, F-3)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Immediate release metformin tablet (Glucophage)
Number of subjects: 12
Study: 14505991

Group type: EXPERIMENTAL
Intervention: Phytosterol ester-enriched vegetable oil (0.45 g/day as free sterol)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control vegetable oil (0.04 g phytosterol as the major free sterol)
Number of subjects: 60
Study: 10811340

Group type: EXPERIMENTAL
Intervention: Interferon and ribavirin (3 million units of alpha‐interferon three times weekly with 1000 mg of ribavirin daily)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Interferon and amantadine (3 million units of alpha‐interferon with 200 mg of amantadine daily)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Interferon and ribavirin
Number of subjects: 29

Group type: COMPARATOR
Intervention: Interferon and amantadine
Number of subjects: 29
Study: 9023837

Group type: EXPERIMENTAL
Intervention: Hydroxyurea during pelvic radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with cisplatin-containing regimens followed by radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy after radiotherapy
Number of subjects: 0
Study: 7816256

Group type: EXPERIMENTAL
Intervention: Desferrioxamine 15 mg/kg administered 1 hour before dialysis
Number of subjects: 10

Group type: COMPARATOR
Intervention: Desferrioxamine 15 mg/kg administered 44 hours before dialysis
Number of subjects: 10
Study: 2897784

Group type: EXPERIMENTAL
Intervention: Nizatidine (300 mg, once daily at bedtime)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Ranitidine (300 mg, once daily at bedtime)
Number of subjects: 141
Study: 28683941

Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 117

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 117
Study: 26413958

Group type: EXPERIMENTAL
Intervention: Minimally invasive harvesting techniques without periosteum elevation (group 1)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Minimally invasive harvesting techniques with periosteum elevation (group 2)
Number of subjects: 56
Study: 23628620

Group type: EXPERIMENTAL
Intervention: High-risk DR3/DR4 genotype
Number of subjects: 1333

Group type: EXPERIMENTAL
Intervention: Full model including HLA information and SNPs from CTLA4 and INS
Number of subjects: 1333

Group type: EXPERIMENTAL
Intervention: Genotype information equivalent to typing four SNPs (DR3, DR4-DQB1*03:02, CTLA-4, and INS)
Number of subjects: 1333
Study: 21337296

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy plus resource activation (RFCBT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Cognitive behavioural therapy (CBT) alone
Number of subjects: 52
Study: 19417872

Group type: EXPERIMENTAL
Intervention: Xylitol lozenges (5 pieces/day, 2 g each) for 4 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: Sorbitol lozenges (5 pieces/day, 2 g each) for 4 weeks
Number of subjects: 61
Study: 18164917

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 15188351

Group type: EXPERIMENTAL
Intervention: MRA (8 mg/kg body weight)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: MRA (4 mg/kg body weight)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study: 11490049

Group type: EXPERIMENTAL
Intervention: Information plus a reinforcement‐to‐change discussion group
Number of subjects: 99

Group type: COMPARATOR
Intervention: Information only
Number of subjects: 99

Group type: COMPARATOR
Intervention: Information plus an innocuous discussion group
Number of subjects: 99
Study: 9731960

Group type: EXPERIMENTAL
Intervention: Mirak Home Care Packs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8521306

Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC) 15-20 micrograms.kg-1
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo lozenge
Number of subjects: 42
Study: 2334454

Group type: EXPERIMENTAL
Intervention: ibopamine solution 1%
Number of subjects: 18

Group type: COMPARATOR
Intervention: tropicamide solution 1%
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: ibopamine solution 0.25% and 0.50%
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 103404

Group type: EXPERIMENTAL
Intervention: Meglumine iotroxate (3.6 g iodine)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Meglumine iodoxamate (5.3 g iodine)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Meglumine ioglycamate (5.3 g iodine)
Number of subjects: 195
Study: 31387429

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ10) supplementation with pregabalin for 40 days
Number of subjects: 11

Group type: COMPARATOR
Intervention: Pregabalin alone
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo with pregabalin
Number of subjects: 11
Study: 28774278

Group type: EXPERIMENTAL
Intervention: Fun 'n healthy in Moreland! intervention
Number of subjects: 2965
Study: 26153485

Group type: EXPERIMENTAL
Intervention: Melker 3.5 in contextualized scenario (CS)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Melker 3.5 in non-contextualized scenario (NCS)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Melker 5.0 in contextualized scenario (CS)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Melker 5.0 in non-contextualized scenario (NCS)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Portex 6.0 in contextualized scenario (CS)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Portex 6.0 in non-contextualized scenario (NCS)
Number of subjects: 65
Study: 23316894

Group type: EXPERIMENTAL
Intervention: Four-handed care
Number of subjects: 10

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 10
Study: 21648056

Group type: EXPERIMENTAL
Intervention: Maternal hot tub use during early pregnancy
Number of subjects: 10825

Group type: EXPERIMENTAL
Intervention: Maternal hot tub use more than once and for more than 30 min
Number of subjects: 10825